JPWO2019228514A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019228514A5 JPWO2019228514A5 JP2021517092A JP2021517092A JPWO2019228514A5 JP WO2019228514 A5 JPWO2019228514 A5 JP WO2019228514A5 JP 2021517092 A JP2021517092 A JP 2021517092A JP 2021517092 A JP2021517092 A JP 2021517092A JP WO2019228514 A5 JPWO2019228514 A5 JP WO2019228514A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 147
- 102000004965 antibodies Human genes 0.000 claims description 68
- 108090001123 antibodies Proteins 0.000 claims description 68
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 230000035693 Fab Effects 0.000 claims description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010017758 Gastric cancer Diseases 0.000 claims description 3
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 3
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 3
- 210000004185 Liver Anatomy 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025650 Malignant melanoma Diseases 0.000 claims description 3
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 210000001635 Urinary Tract Anatomy 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 108091006028 chimera Proteins 0.000 claims description 3
- 201000011231 colorectal cancer Diseases 0.000 claims description 3
- 150000002019 disulfides Chemical class 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims description 2
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/089672 | 2018-06-01 | ||
| PCT/CN2018/089672 WO2019227490A1 (en) | 2018-06-01 | 2018-06-01 | Compositions and methods for imaging |
| CN2018099556 | 2018-08-09 | ||
| CNPCT/CN2018/099556 | 2018-08-09 | ||
| PCT/CN2019/089606 WO2019228514A1 (en) | 2018-06-01 | 2019-05-31 | Compositions and uses thereof for treating disease or condition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021525806A JP2021525806A (ja) | 2021-09-27 |
| JPWO2019228514A5 true JPWO2019228514A5 (ru) | 2022-06-08 |
Family
ID=68698693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517092A Pending JP2021525806A (ja) | 2018-06-01 | 2019-05-31 | 疾患または状態を処置するための組成物およびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210214444A1 (ru) |
| EP (1) | EP3818085A4 (ru) |
| JP (1) | JP2021525806A (ru) |
| KR (1) | KR20210056288A (ru) |
| CN (2) | CN117442717A (ru) |
| AU (1) | AU2019275737A1 (ru) |
| BR (1) | BR112020023505A2 (ru) |
| CA (1) | CA3102230A1 (ru) |
| MX (1) | MX2020012613A (ru) |
| WO (1) | WO2019228514A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3914623A4 (en) * | 2019-01-23 | 2022-11-23 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-L1 DIABODIES AND THEIR USE |
| CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
| CA3185858A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| CA3190328A1 (en) | 2020-07-29 | 2022-02-03 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| CN115073599B (zh) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | 结合pd-l1的抗体及其用途 |
| EP4314049A1 (en) | 2021-03-25 | 2024-02-07 | Dynamicure Biotechnology LLC | Anti-igfbp7 constructs and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| MY175472A (en) * | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| US20170320954A1 (en) * | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| AU2015355137A1 (en) * | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
| CA2976360A1 (en) * | 2015-02-11 | 2016-08-18 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN109715821B (zh) * | 2016-01-29 | 2022-09-06 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
| MX2017016851A (es) * | 2016-03-04 | 2018-04-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. |
| PE20190510A1 (es) * | 2016-06-13 | 2019-04-10 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos |
-
2019
- 2019-05-31 WO PCT/CN2019/089606 patent/WO2019228514A1/en unknown
- 2019-05-31 BR BR112020023505-9A patent/BR112020023505A2/pt unknown
- 2019-05-31 CN CN202310187485.9A patent/CN117442717A/zh active Pending
- 2019-05-31 JP JP2021517092A patent/JP2021525806A/ja active Pending
- 2019-05-31 AU AU2019275737A patent/AU2019275737A1/en active Pending
- 2019-05-31 CA CA3102230A patent/CA3102230A1/en active Pending
- 2019-05-31 KR KR1020207037789A patent/KR20210056288A/ko unknown
- 2019-05-31 MX MX2020012613A patent/MX2020012613A/es unknown
- 2019-05-31 EP EP19810897.9A patent/EP3818085A4/en active Pending
- 2019-05-31 US US15/733,838 patent/US20210214444A1/en active Pending
- 2019-05-31 CN CN201980051359.2A patent/CN112533952B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| TWI640537B (zh) | ＰＤＧＦ受體β結合多肽 | |
| JP2020504627A (ja) | 抗ｐｄ−１抗体及びその使用 | |
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JP2003525061A5 (ru) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| WO2021063349A1 (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| US11110179B2 (en) | Combination of CD33 antibody drug conjugates with chemotherapeutic agents | |
| JP2024016024A5 (ru) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| WO2023036281A1 (zh) | 抗cd47抗体及其用途 | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| US20180296691A1 (en) | Anti-efna4 antibody-drug conjugates | |
| CN113135995A (zh) | 抗her3单克隆抗体及其应用 | |
| JPWO2021213434A5 (ru) | ||
| JPWO2019228514A5 (ru) | ||
| WO2022179466A1 (zh) | 抗Siglec15抗体及其用途 | |
| EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
| WO2021139687A1 (zh) | 抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用 | |
| JPWO2022114163A5 (ru) | ||
| EP4054590A1 (en) | Methods for treating leukemia | |
| JPWO2019243159A5 (ru) | ||
| JPWO2020218951A5 (ru) | ||
| Albrecht et al. | Fundamentals of antibody-related therapy and diagnostics | |
| JPWO2021063201A5 (ru) |